Tactical Adaptations in Antibiotic Development for Virtual Biotechs

A virtual biotech company chose Covance to conduct two Phase III clinical trials for a new antibiotic treating life-threatening skin infections, such as methicillin-resistant staphylococcus aureus (MRSA). The Xcellerate Protocol Design tool and Xcellerate Site List Tool enabled Covance to identify optimal sites and high-performing investigators quickly, ensuring rapid selection and startup of appropriate sites and accelerated rate of patient enrollment which kept the trials on track and within budget.